Eribulin

Evidence Level: L5

Predicted Indications: 9

Eribulin

Pharmacist Assessment Report

Eribulin: From Liposarcoma to Autosomal Recessive Familial Mediterranean Fever

One-Sentence Summary

Eribulin is a microtubule-targeting cytotoxic chemotherapy, originally used for liposarcoma. The TxGNN model (deep learning) predicts it may be effective for autosomal recessive familial Mediterranean fever, but no clinical trials and no publications currently support this prediction. The score comes from the TxGNN model and may reflect similarities the model learned between related diseases, not biological evidence.

Quick Overview

Item	Content
Original Indication	Liposarcoma
Predicted New Indication	Autosomal recessive familial Mediterranean fever
TxGNN Prediction Score	0.9982
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (8 of 8) – CDSCO approval status is not included in this data
Number of Listed Products	8 (valid: 8)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Eribulin is a synthetic analog of halichondrin B that inhibits microtubule dynamics. It is used in cytotoxic oncology. Detailed mechanism-of-action data were not available in the data compiled for this report, so the mechanistic description relies on its known drug class.

Familial Mediterranean fever is an autoinflammatory disease driven by dysregulation of the pyrin inflammasome. The standard therapy, colchicine, is also a microtubule-targeting agent. This shared target class may explain the high model score. However, eribulin binds tubulin differently from colchicine. Its cytotoxic profile is also unsuitable for a chronic, non-malignant condition. The score is therefore most likely a TxGNN model (deep learning) artifact rather than a true mechanistic signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Eribulin is marketed in India as an injectable. Eight valid single-ingredient registrations are on file. The approved indication text was not available for these registrations, so it is not shown. The table lists the first five.

Authorization Number	Product Name	Dosage Form
Registration No. 75829	Ebunat 0.5mg Injection (Natco Pharma Ltd)	Vial of 1 Injection
Registration No. 75269	Eribilin Injection (Emcure Pharmaceuticals Ltd)	Vial of 2 ml Solution for Injection
Registration No. 77600	Epbriv 0.44mg Injection (Hetero Healthcare Limited)	Vial of 2 ml Injection
Registration No. 104185	Halaven 1mg Injection (Eisai Pharmaceuticals India Pvt Ltd)	Vial of 2 ml Injection
Registration No. 75256	Embremma Injection (Emcure Pharmaceuticals Ltd)	Vial of 2 ml Injection

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (microtubule dynamics inhibitor)
Myelosuppression Risk	High. Neutropenia and thrombocytopenia appear among the knowledge-graph contraindication-related conditions
Emetogenicity Classification	Low to moderate (general drug-class knowledge)
Monitoring Items	CBC with differential, liver and renal function, electrolytes (including potassium), ECG/QT, and peripheral neuropathy assessment
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Conditions flagged in the knowledge graph (not label text): long QT syndrome (including familial), thrombocytopenia, neutropenia, agranulocytosis, potassium deficiency, peripheral neuropathy and other peripheral nervous system disease, and constipation disorder.
Drug Interactions: 375 interactions were identified.
- Major: dolasetron and cisapride, both QT-prolonging agents.
- Moderate: ondansetron, palonosetron, clarithromycin, levofloxacin, metronidazole, tinidazole, famotidine, loperamide, rosuvastatin and simvastatin. Several laxatives and bowel-preparation agents also appear, such as bisacodyl, lactulose, lactitol, castor oil, sodium sulfate and polyethylene glycol.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on model score alone (L5), with no trials or publications. The mechanistic link is weak, and a cytotoxic agent with significant myelosuppression and QT-related risks is a poor fit for a chronic autoinflammatory disease. Established therapies such as colchicine already exist.

To proceed, the following is needed:

Any mechanistic or preclinical evidence linking eribulin to pyrin inflammasome regulation
Detailed mechanism-of-action data
Package insert warnings and contraindications from the India regulatory source
A risk-benefit assessment for a non-malignant chronic indication

Note on other predictions: Among the other model predictions, fibroblastic neoplasm (rank 8, score 0.9936) has the strongest support. It has a completed Phase 2 trial of eribulin in advanced solitary fibrous tumor (ERASING, NCT03840772, n=16) and supportive preclinical literature. Its results were not available, so efficacy is unconfirmed. If this evaluation is redirected toward oncology, that indication is the more promising candidate for follow-up.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.